Showing results (1911-1920 of 1,985) with videos related to

Sort By:
Pageof 199
The Lancet. Neurology|January 28, 2014
Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trialChristian Confavreux, Paul O'Connor, Giancarlo Comi, et al.
The Lancet. Neurology|May 20, 2014
Simvastatin in aneurysmal subarachnoid haemorrhage (STASH): a multicentre randomised phase 3 trialPeter J Kirkpatrick, Carole L Turner, Christopher Smith, et al.
The Lancet. Neurology|November 6, 2012
Effects of systolic blood pressure on white-matter integrity in young adults in the Framingham Heart Study: a cross-sectional studyPauline Maillard, Sudha Seshadri, Alexa Beiser, et al.
The Lancet. Neurology|November 17, 2012
Measurement and clinical effect of grey matter pathology in multiple sclerosisJeroen J G Geurts, Massimiliano Calabrese, Elizabeth Fisher, et al.
The Lancet. Neurology|August 13, 2022
Incremental prognostic value of acute serum biomarkers for functional outcome after traumatic brain injury (CENTER-TBI): an observational cohort studyIsabel R A Retel Helmrich, Endre Czeiter, Krisztina Amrein, et al.
The Lancet. Neurology|February 21, 2023
Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trialRichard B Lipton, Robert Croop, David A Stock, et al.
The Lancet. Neurology|March 27, 2023
Personalised virtual brain models in epilepsyViktor Jirsa, Huifang Wang, Paul Triebkorn, et al.
The Lancet. Neurology|May 30, 2020
Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a cross-sectional analysisRachael I Scahill, Paul Zeun, Katherine Osborne-Crowley, et al.
The Lancet. Neurology|May 30, 2020
Advances in the diagnosis of inherited neuromuscular diseases and implications for therapy developmentRachel Thompson, Sally Spendiff, Andreas Roos, et al.
The Lancet. Neurology|November 19, 2022
Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trialMichael J Soileau, Jason Aldred, Kumar Budur, et al.
Pageof 199